Venetoclax-Decitabine in Untreated Elderly/Unfit AML

Acute myeloid leukemia (AML) is a highly fatal malignancy in China, with particularly poor outcomes in elderly patients. Low-intensity regimens yield low remission rates, and median overall survival (OS) typically remains under 6-9 months. Venetoclax (VEN) combined with hypomethylating agents (azacitidine or decitabine(DEC)) has emerged as a first-line therapy for these patients, significantly improving response rates and survival. However, challenges persist, including suboptimal complete remission (CR) rates, low Measurable Residual Disease(MRD) negativity, and tolerability issues with prolo

Trial Details

NCT ID
NCT07117422
Phase
NA
Sponsor
The Second Hospital of Hebei Medical University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • VEN + DEC
Locations (sample)
  • Hebei, China|25.93504,116.17968

Key Eligibility Criteria

  • Patients meeting the World Health Organization (WHO) 2022 diagnostic criteria for acute myeloid leukemia (AML), excluding:Acute promyelocytic leuke…
  • AML with recurrent genetic abnormalities, including:t(8;21)(RUNX1::RUNX1T1)
  • inv(16)(p13.1q22) or t(16;16)(p13.1q22)/CBFβ::MYH11
  • Patients classified as AML, not otherwise specified (NOS) per WHO criteria, excluding:Acute panmyelosis with myelofibrosis 、Myeloid sarcoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →